Serum Osteoprotegerin Is Associated Independently with Peripheral Arterial Stiffness in Chronic Kidney Disease
Diagnostics · 19.06.2026 · 16 (12) · 1906
DOI: 10.3390/diagnostics16121906 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 19.06.2026. Verfasst von Yahn-Bor Chern und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Yuan's General Hospital, Kaohsiung 802635, Taiwan. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tzu Chi Foundation, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Abstract (Originalsprache)
Background/Objectives: Patients with chronic kidney disease (CKD) often present with peripheral arterial stiffness (PAS), which is associated with an increased cardiovascular risk. This study assessed the association between circulating osteoprotegerin (OPG), a known mediator of vascular calcification, and PAS, measured as brachial–ankle pulse wave velocity (baPWV), in patients with CKD.
Methods
This cross-sectional investigation engaged 200 individuals with non-dialysis CKD. Serum OPG concentrations were measured using a commercial enzyme-linked immunosorbent assay. Participants were classified as having PAS when either left or right baPWV was greater than 18.0 m/s; those with baPWV values of 18.0 m/s or lower were assigned to the control group.
Results
Eighty-six patients (43.0%) had PAS. In comparison to controls, PAS patients were older (p < 0.001) and had higher proportions of diabetes mellitus (p = 0.023) and hypertension (p = 0.010); systolic blood pressure was higher (p < 0.001), urine protein-to-creatinine ratio was elevated (p = 0.004), and serum OPG was markedly greater (p < 0.001), whereas estimated glomerular filtration rate was lower (p = 0.003). After full adjustment, OPG levels, in addition to older age and diabetes mellitus, demonstrated an independent association with PAS (odds ratio: 1.008; 95% confidence interval: 1.002–1.015; p = 0.010). The OPG level was positively associated with bilateral baPWV by Spearman’s correlation analysis (p < 0.001).
Conclusions
Circulating OPG level showed an independent association with PAS and baPWV in CKD patients not yet on dialysis. Hence, OPG can be a potential marker of vascular risk in this patient population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Yuan's General Hospital, Kaohsiung 802635, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan.
- Division of Nephrology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97004, Taiwan.
- Department of Pharmacology, School of Medicine, Tzu Chi University, Hualien 97004, Taiwan.
- School of Medicine, Tzu Chi University, Hualien 97004, Taiwan.
ORCID-Profile: Yahn-Bor Chern, Po-Yu Huang, Yu-Hsien Lai, Chih-Hsien Wang, Jen-Pi Tsai, Bang-Gee Hsu
Förderung
- Tzu Chi Foundation
- Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
Zitieren
APA
Chern, Y. B., Huang, P. Y., Lai, Y. H., Wang, C. H., Tsai, J. P., & Hsu, B. G. (2026). Serum Osteoprotegerin Is Associated Independently with Peripheral Arterial Stiffness in Chronic Kidney Disease. Diagnostics, 16(12), 1906. https://doi.org/10.3390/diagnostics16121906
Vancouver
Chern YB, Huang PY, Lai YH, Wang CH, Tsai JP, Hsu BG. Serum Osteoprotegerin Is Associated Independently with Peripheral Arterial Stiffness in Chronic Kidney Disease. Diagnostics. 2026;16(12):1906. doi:10.3390/diagnostics16121906
BibTeX
@article{Chern2026,
author = {Chern, Yahn-Bor and Huang, Po-Yu and Lai, Yu-Hsien and Wang, Chih-Hsien and Tsai, Jen-Pi and Hsu, Bang-Gee},
title = {Serum Osteoprotegerin Is Associated Independently with Peripheral Arterial Stiffness in Chronic Kidney Disease},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {12},
pages = {1906},
doi = {10.3390/diagnostics16121906}
}
EUVIMED